Response to Hydralazine-Valproate in a Patient with Mycosis Fungoides

Histone deacetylase (HDAC) inhibitors have shown significant activity in the treatment of cutaneous T-cell lymphomas (CTCL). The epigenetic alterations of CTCL not only are limited to altered histone acetylation but also include aberrant DNA gene methylation hence, the combination of an HDAC inhibit...

Descripción completa

Detalles Bibliográficos
Autores principales: Dueñas-Gonzalez, Alfonso, Vega, Maria Teresa, Martinez-Baños, Déborah, García-Hidalgo, Linda, Sobrevilla, Pedro
Formato: Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2010
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2842973/
https://www.ncbi.nlm.nih.gov/pubmed/20339522
http://dx.doi.org/10.1155/2010/657579
Descripción
Sumario:Histone deacetylase (HDAC) inhibitors have shown significant activity in the treatment of cutaneous T-cell lymphomas (CTCL). The epigenetic alterations of CTCL not only are limited to altered histone acetylation but also include aberrant DNA gene methylation hence, the combination of an HDAC inhibitor with a DNA demethylating agent is a promising therapy to be tested. Here we report a mycosis fungoides patient having a dramatic response to hydralazine and valproate, two repositioned drugs as HDAC and DNA methylation inhibitors, respectively.

Ejemplares similares